Antibody-based immunotherapeutic attempts in experimental animal models of prion diseases

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 7, 2009, Pages 907-917

  Sakaguchi, Suehiro ^a   Ishibashi, Daisuke ^b   Matsuda, Haruo ^c  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Antibody; Immunotherapy; Prion; Prion diseases; Prion protein

Indexed keywords

ANTIHISTAMINIC AGENT; CYSTEINE PROTEINASE INHIBITOR; DOXYCYCLINE; FLUPIRTINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; LENTIVIRUS VECTOR; MEPACRINE; MINOCYCLINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 110; MONOCLONAL ANTIBODY 2H9; MONOCLONAL ANTIBODY 31C6; MONOCLONAL ANTIBODY 3S9; MONOCLONAL ANTIBODY D13; MONOCLONAL ANTIBODY ICSM 18; MONOCLONAL ANTIBODY ICSM 35; MONOCLONAL ANTIBODY LAMININ RECEPTOR; MONOCLONAL ANTIBODY P; PENTOSAN POLYSULFATE; POLYANION; POLYCATION; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY W3; POLYENE ANTIBIOTIC AGENT; PRION PROTEIN ANTIBODY; TETRAPYRROLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NEUROTOXICITY; NONHUMAN; PRION DISEASE; PROTEIN TARGETING; REVIEW; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES; CATTLE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY; PATENTS AS TOPIC; PRION DISEASES; PRIONS;

EID: 67650407709     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902988530     Document Type: Review

References (86)

1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95(23):13363-13383
2. DeArmond SJ, Prusiner SB. Etiology and pathogenesis of prion diseases. Am J Pathol 1995;146(4):785-811
3. Duffy P, Wolf J, Collins G, et al. Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med 1974;290(12):692-693
4. Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1977;1(8009):478-479 (Pubitemid 8045134)
5. Koch TK, Berg BO, De Armond SJ, Gravina RF. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth hormone. N Engl J Med 1985;313(12):731-733 (Pubitemid 15232428)
6. Thadani V, Penar PL, Partington J, et al. Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. Case report. J Neurosurg 1988;69(5):766-769 (Pubitemid 18258053)
7. Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977;197(4307):943-960 (Pubitemid 8166348)
8. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997;389(6650):498-501 • Describes probable transmission of BSE to humans.
9. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997;389(6650):448-450, 526 • Describes probable transmission of BSE to humans.
10. Collee JG, Bradley R, Liberski PP. Variant CJD (vCJD) and bovine spongiform encephalopathy (BSE): 10 and 20 years on: part 2. Folia Neuropathol 2006;44(2):102-110
11. Prusiner SB. Prion diseases and the BSE crisis. Science 1997;278(5336):245-251
12. Available from: http://www.cjd.ed.ac.uk/figures.htm
13. Available from: http://niah.naro.affrc.go.jp/disease/bse/count.html
14. Williams ES. Chronic wasting disease. Vet Pathol 2005;42(5):530-549
15. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363(9407):417-421 •• Describes the first case of possible human-to-human transmission of vCJD via blood transfusion.
16. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364(9433):527-529 •• Describes possible transmission of vCJD to human carrying an M/V 129 codon via blood transfusion.
17. Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006;368(9552):2061-2067
18. Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transfus Med Rev 2008;22(1):58-69 (Pubitemid 350184249)
19. Brandel JP, Preece M, Brown P, et al. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet 2003;362(9378):128-130 (Pubitemid 36831026)
20. Cervenakova L, Goldfarb LG, Garruto R, et al. Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA 1998;95(22):13239-13241 (Pubitemid 28509555)
21. Wadsworth JD, Asante EA, Desbruslais M, et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 2004;306(5702):1793-1796 (Pubitemid 39601400)
22. Bishop MT, Hart P, Aitchison L, et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 2006;5(5):393-398
23. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004;203(3):733-9 •• Describes a possibility of a large number of people subclinically infected by vCJD.
24. Prusiner SB. Molecular biology of prion diseases. Science 1991;252(5012):1515-1522
25. Oesch B, Westaway D, Walchli M, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 1985;40(4):735-746 (Pubitemid 15240279)
26. Bueler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993;73(7):1339-1347 (Pubitemid 23201147)
27. Prusiner SB, Groth D, Serban A, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci USA 1993;90(22):10608-10612 (Pubitemid 23347091)
28. Sakaguchi S, Katamine S, Shigematsu K, et al. Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent. J Virol 1995;69(12):7586-7592
29. Manson JC, Clarke AR, McBride PA, et al. PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration 1994;3(4):331-340
30. Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003;302(5646):871-874 (Pubitemid 37339628)
31. Mallucci GR, White MD, Farmer M, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 2007;53(3):325-335 (Pubitemid 46161264)
32. Yokoyama T, Kimura KM, Ushiki Y, et al. Invivo conversion of cellular prion protein to pathogenic isoforms, as monitored by conformation-specific antibodies. J Biol Chem 2001;276(14):11265-11271 (Pubitemid 38089314)
33. Tobler I, Gaus SE, Deboer T, et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 1996;380(6575):639-642 (Pubitemid 26119019)
34. Nishida N, Tremblay P, Sugimoto T, et al. A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. Lab Invest 1999;79(6):689-697 (Pubitemid 29283422)
35. Gambetti P, Parchi P, Petersen RB, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. Brain Pathol 1995;5(1):43-51
36. Neufeld MY, Josiphov J, Korczyn AD. Demyelinating peripheral neuropathy in Creutzfeldt-Jakob disease. Muscle Nerve 1992;15(11):1234-1239
37. Forloni G, Angeretti N, Chiesa R, et al. Neurotoxicity of a prion protein fragment. Nature 1993;362(6420):543-546
38. Muller WE, Ushijima H, Schroder HC, et al. Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. Eur J Pharmacol 1993;246(3):261-267 (Pubitemid 23253684)
39. Hetz C, Russelakis-Carneiro M, Maundrell K, et al. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J 2003;22(20):5435-5445 (Pubitemid 37279953)
40. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006;129(Pt 9):2241-65 •• Systematically reviews anti-prion molecules.
41. Sakaguchi S. Recent developments in therapeutics for prion diseases. Expert Opin Ther Patents 2008;18(1):35-59 •• Systematically reviews anti-prion molecules.
42. De Luigi A, Colombo L, Diomede L, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE 2008;3(3):e1888 (Pubitemid 351943730)
43. Gauczynski S, Nikles D, El-Gogo S, et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis 2006;194(5):702-709 (Pubitemid 44297858)
44. Rainov NG, Tsuboi Y, Krolak-Salmon P, et al. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin Biol Ther 2007;7(5):713-726
45. Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008;15(5):458-464
46. Available from: http://www.ctu.mrc.ac.uk/studies/cjd.asp
47. Nakajima M, Yamada T, Kusuhara T, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2004;17(3):158-163 (Pubitemid 38339741)
48. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62(5):714-718 (Pubitemid 38298945)
49. Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001;412(6848):739-43 •• The first paper describing a possibility of antibody-based immunotherapy against prion diseases.
50. Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 2001;98(16):9295-9299 (Pubitemid 32743910)
51. Harris DA. Cellular biology of prion diseases. Clin Microbiol Rev 1999;12(3):429-444
52. Kaneko K, Peretz D, Pan KM, et al. Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Proc Natl Acad Sci USA 1995;92(24):11160-11164
53. Horiuchi M, Caughey B. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 1999;18(12):3193-3203 (Pubitemid 29276566)
54. Kim CL, Karino A, Ishiguro N, et al. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 2004;85(Pt 11):3473-3482 (Pubitemid 39445468)
55. Perrier V, Solassol J, Crozet C, et al. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 2004;89(2):454-463 (Pubitemid 38495993)
56. Rieger R, Edenhofer F, Lasmezas CI, Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 1997;3(12):1383-8 •• The first paper describing interaction between LRP/LR and PrPC.
57. Hundt C, Peyrin JM, Haik S, et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J 2001;20(21):5876-5886 (Pubitemid 33049263)
58. Gauczynski S, Peyrin JM, Haik S, et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001;20(21):5863-75 •• Demonstrates LRP/LR as the receptor for PrPC.
59. Leucht C, Simoneau S, Rey C, et al. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep 2003;4(3):290-295 (Pubitemid 36511726)
60. Ludewigs H, Zuber C, Vana K, et al. Therapeutic approaches for prion disorders. Expert Rev Anti Infect Ther 2007;5(4):613-630
61. Vana K, Zuber C, Nikles D, Weiss S. Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy. Cell Mol Neurobiol 2007;27(1):107-128 (Pubitemid 46169898)
62. Vana K, Zuber C, Pflanz H, et al. LRP/LR as an alternative promising target in therapy of prion diseases, Alzheimer's disease and cancer. Infect Disord Drug Targets 2009;9(1):69-80
63. Zuber C, Ludewigs H, Weiss S. Therapeutic approaches targeting the prion receptor LRP/LR. Vet Microbiol 2007;123(4):387-393 (Pubitemid 47088870)
64. Miyamoto K, Nakamura N, Aosasa M, et al. Inhibition of prion propagation in scrapie-infected mouse neuroblastoma cell lines using mouse monoclonal antibodies against prion protein. Biochem Biophys Res Commun 2005;335(1):197-204 (Pubitemid 41350780)
65. Medical Res Council (GB). US2006280745; 2006
66. White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003;422(6927):80-3 •• Describes the first successful passive immunization against prion disease.
67. Song CH, Furuoka H, Kim CL, et al. Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J Gen Virol 2008;89(Pt 6):1533-1544
68. Lefebvre-Roque M, Kremmer E, Gilch S, et al. Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice. Prion 2007;1(3):198-206
69. Kagoshima Univ (JP); Search Inst Juridical Foundati (JP); Sugimura Kazuhisa (JP); Nakashima Toshihiro (JP). WO2006046344; 2006
70. Donofrio G, Heppner FL, Polymenidou M, et al. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 2005;79(13):8330-8338 (Pubitemid 40853536)
71. Campana V, Zentilin L, Mirabile I, et al. Development of antibody fragments for immunotherapy of prion diseases. Biochem J 2008;418(3):507-515
72. Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 2008;16(3):481-486 (Pubitemid 351314986)
73. Mandel RJ, Manfredsson FP, Foust KD, et al. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 2006;13(3):463-483 (Pubitemid 43257615)
74. Tenenbaum L, Chtarto A, Lehtonen E, et al. Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med 2004;6(Suppl 1):S212-22 (Pubitemid 40228030)
75. Li ZJ, Wang RZ. rAAV vector-mediated gene therapy for experimental ischemic stroke. Neurol India 2008;56(2):116-121
76. Beck SE, Jones LA, Chesnut K, et al. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol 1999;73(11):9446-9455 (Pubitemid 29487100)
77. Halbert CL, Rutledge EA, Allen JM, et al. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000;74(3):1524-1532 (Pubitemid 30044103)
78. Lo WD, Qu G, Sferra TJ, et al. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther 1999;10(2):201-213 (Pubitemid 29070634)
79. Mastakov MY, Baer K, Symes CW, et al. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol 2002;76(16):8446-8454 (Pubitemid 34809096)
80. Solforosi L, Criado JR, McGavern DB, et al. Cross-linking cellular prion protein triggers neuronal apoptosis invivo. Science 2004;303(5663):1514-1516 (Pubitemid 38314420)
81. Zuber C, Mitteregger G, Pace C, et al. Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice. Prion 2007;1(3):207-212
82. Zuber C, Knackmuss S, Rey C, et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2008;45(1):144-151 (Pubitemid 47336972)
83. Weiss Stefan (DE); Little Melvyn (DE); Knackmuss Stefan (DE); Rey Clemence (DE); Roettgen Peter (DE); Buettner Claudia (DE); Reusch Uwe (DE). WO2005035580; 2005
84. Zuber C, Mitteregger G, Schuhmann N, et al. Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol 2008;89(Pt 8):2055-2061
85. Meier P, Genoud N, Prinz M, et al. Soluble dimeric prion protein binds PrP(Sc) invivo and antagonizes prion disease. Cell 2003;113(1):49-60 (Pubitemid 36411959)
86. Genoud N, Ott D, Braun N, et al. Antiprion prophylaxis by gene transfer of a soluble prion antagonist. Am J Pathol 2008;172(5):1287-1296 (Pubitemid 351671541)